The HDAC1/2/6 inhibitor MPT0B291 has been reported to enhance Sp1 acetylation, increase TMZ sensitivity in GBM cells, and prolong survival in drug-resistant orthotopic transplantation models [253]. This evidence concerns the gene HDAC1 and glioblastoma.